We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · May 26, 2022

Barriers and Facilitators Associated With Obtaining an X-Waiver and Prescribing Buprenorphine

JAMA Network Open


Additional Info

JAMA Network Open
Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver
JAMA Netw Open 2022 May 02;5(5)e2212419, HJ Lanham, J Papac, DI Olmos, EL Heydemann, N Simonetti, S Schmidt, JS Potter

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading